News

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

Read more

Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights

Read more

Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib

Read more

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

Read more

Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program

Read more

Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial

Read more

Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more

Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)

Read more

Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting

Read more

Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares

Read more

Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives

Read more

Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance

Read more

Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer

Read more

Allarity Therapeutics Regains Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement

Read more

Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances

Read more

Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock

Read more

Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1

Read more

Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer

Read more

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

Read more

Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

Read more

Quick Links

Investor Email Alerts